Device and method for determining analyte levels

• US 8,155,723 B2
• Filed: 01/28/2010
• Issued: 04/10/2012
• Est. Priority Date: 03/04/1997
• Status: Expired due to Fees

• Current Assignee: DexCom Incorporated
• Original Assignee: DexCom Incorporated
• Inventors: Shults, Mark C., Updike, Stuart J., Rhodes, Rathbun K., Gilligan, Barbara J., Tapsak, Mark A.
• Primary Examiner(s): Mallari, Patricia
• Assistant Examiner(s): JANG, CHRISTIAN YONGKYUN
• Application Number:
  US12/696,003
• Publication Number:
  US 20100160760A1
• Time in Patent Office: 803 Days
• Field of Search: 600/345, 600/347, 600/365
• US Class Current: 600/345
• CPC Class Codes: A61B 5/0031 Implanted circuitry
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/14558 by polarisation
• CPC Class Codes: A61B 5/14865 invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
• CPC Class Codes: C12Q 1/006 for glucose

Abstract

Devices and methods for determining analyte levels are described. The devices and methods allow for the implantation of analyte-monitoring devices, such as glucose monitoring devices that result in the delivery of a dependable flow of blood to deliver sample to the implanted device. The devices include unique architectural arrangement in the sensor region that allows accurate data to be obtained over long periods of time.

Claims

1. An implantable device for measuring an analyte, the device comprising:

a sensor body comprising a sensor configured to measure an analyte; and

a composite bilayer membrane comprising an angiogenic material configured to promote angiogenesis and a bioprotective membrane disposed on at least a portion of the sensor, wherein the bioprotective membrane comprises polycarbonate urethane and polyvinylpyrrolidone, and wherein the angiogenic material is adjacent to the bioprotective membrane.

2. The device of claim 1, wherein the bioprotective membrane comprises pores having pore sizes of from about 0.1 micron to about 1 micron.

3. The device of claim 1, wherein the bioprotective membrane further comprises at least one material selected from the group consisting of polytetrafluoroethylene, polypropylene, polysulfone, and polyethylene terephthalate.

4. The device of claim 1, wherein the angiogenic material comprises expanded polytetrafluoroethylene.